Christopher Haqq, EVP, R&D & Chief Scientific Of at Atara Biotherapeutics, Inc. (ATRA), sold 49,500 shares at $40.53 ($2.0M) on 2018-09-24, disclosed to the SEC on 2018-09-25.
Seasonal sale ($2.0M) by EVP, R&D & Chief Scientific Of — this insider has traded ATRA in September in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.74 | 14,069 | $559K | 28.2% |
| 2 | $39.74 | 14,069 | $559K | 28.2% |
| 3 | $40.53 | 3,931 | $159K | 8.0% |
| 4 | $40.53 | 3,931 | $159K | 8.0% |
| 5 | $40.26 | 10,000 | $403K | 20.3% |
| 6 | $41.23 | 3,500 |
| $144K |
| 7.3% |
| Total | $40.08 avg | 49,500 | $2.0M | 100% |
| Filing → |
| ATRA | SELL | 2019-02-08 | $956K | — | Filing → |
| ATRA | SELL | 2018-11-15 | $26K | — | Filing → |
| ATRA | SELL | 2018-09-27 | $582K | — | Filing → |